A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies

Noelia Silva-Pilipich 1, Cristian Smerdou 1,* and Lucía Vanrell 2,3,*

1 Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra and Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain; nsilva.1@alumni.unav.es
2 Biotechnology Laboratory, Facultad de Ingeniería, Universidad ORT Uruguay, Mercedes 1237, Montevideo 11100, Uruguay
3 Nanogrow Biotech, CIE BIO Incubator, Mercedes 1237, Montevideo 11100, Uruguay
* Correspondence: csmerdou@unav.es (C.S.); lvanrell@gmail.com (L.V.); Tel.: +34-948194700 (C.S.); +508-29021505 (L.V.); Fax: +34-948194717 (C.S.)

Abstract: Nanobodies are camelid-derived single-domain antibodies that present some advantages versus conventional antibodies, such as a smaller size, and higher tissue penetrability, stability, and hydrophilicity. Although nanobodies can be delivered as proteins, in vivo expression from adeno-associated viral (AAV) vectors represents an attractive strategy. This is due to the fact that AAV vectors, that can provide long-term expression of recombinant genes, have shown an excellent safety profile, and can accommodate genes for one or several nanobodies. In fact, several studies showed that AAV vectors can provide sustained nanobody expression both locally or systemically in preclinical models of human diseases. Some of the pathologies addressed with this technology include cancer, neurological, cardiovascular, infectious, and genetic diseases. Depending on the indication, AAV-delivered nanobodies can be expressed extracellularly or inside cells. Intracellular nanobodies or “intrabodies” carry out their function by interacting with cell proteins involved in disease and have also been designed to help elucidate cellular mechanisms by interfering with normal cell processes. Finally, nanobodies can also be used to retarget AAV vectors, when tethered to viral capsid proteins. This review covers applications in which AAV vectors have been used to deliver nanobodies, with a focus on their therapeutic use.

Keywords: adeno-associated virus; AAV; nanobody; antibody; gene therapy

1. Adeno-Associated Viral Vectors

Adeno-associated virus (AAV) is a small, non-enveloped, and non-pathogenic virus that belongs to the Parvoviridae family. AAV cannot replicate by itself, needing the presence of a helper virus, such as adenovirus, for propagation. The AAV particle contains an icosahedral capsid consisting of 60 copies of three related proteins, VP1, VP2, and VP3 (with a 1:1:8 ratio), which surrounds a 4.7 kb single-stranded DNA genome flanked by two palindromic inverted terminal repeats (ITRs) of 145 bp. The viral genome comprises two open reading frames: rep and cap. Rep encodes four non-structural proteins, while cap encodes the capsid proteins and the assembly-activating protein (AAP) [1].

In AAV vectors, all viral genes are replaced by the gene of interest [1], leaving only the ITRs, which serve as origin of replication and packaging signals during vector production. These sequences also allow long-term episomal persistence of the therapeutic transgene in the nucleus of transduced cells [2].

For AAV vector production, rep and cap genes are provided in trans, along with the necessary helper virus genes [3]. There are at least 12 serotypes of AAV with different tropisms, and more than 100 AAV variants, from which a wide variety of mutants have been generated to optimize the delivery of genes to different target tissues [4]. To take advantage of the full potential of such variants, it is possible to package the therapeutic
construct flanked by AAV2 ITRs into capsids of different serotypes (or mutants), a process referred to as pseudo-packaging [5].

AAV vectors are highly stable and easy to produce. Furthermore, they have an excellent safety profile and have shown high transduction efficiency in various target tissues, transducing both quiescent and dividing cells, and allowing long-term expression of the transgene in animal models [6]. For these reasons, they have become the leading viral vectors for in vivo gene delivery, not only in pre-clinical investigation but also to treat a variety of human diseases in clinical stages, including bleeding, musculoskeletal and lysosomal storage disorders, inherited blindness, and neurodegenerative diseases, among others [4,7,8].

As a limitation, the packaging capacity of AAV is low, being approximately 5 kb. Furthermore, the recombinant episomal forms of AAV do not replicate during mitosis of dividing cells, so the therapeutic effect would fade after several generations [9]. Nevertheless, strategies to maintain AAV episomes after cell division by incorporating autonomous replication units into the vector genome [10] or to integrate rAAV genomes at specific sites have been developed [11,12].

Moreover, the host’s immune response can be a major obstacle in AAV vector translation to the clinic due to both innate [13] and adaptive immune responses that can hamper AAV transduction (the latter consisting of cytotoxic T lymphocytes and antibodies against capsid proteins and/or the therapeutic protein) [14]. To counteract the immune-mediated clearance of transduced cells, transient immunosuppressive treatments, AAV capsid engineering strategies, or a combination approach have been proposed (reviewed in [4]).

While AAV vectors have gained significant attention as gene therapy vectors for rare inherited monogenic diseases, their use is not limited to these pathologies. Thanks to a number of factors including early approval by regulatory agencies, an excellent safety profile, availability of large-scale production, and the versatility of vector tailoring through genetic engineering, AAV vectors are showing a great potential to treat a broad range of diseases. These vectors are particularly suitable to provide sustained expression of therapeutic proteins in serum, including therapeutic antibodies. In fact, studies in non-human primates have shown that AAV vectors can provide long-term expression of broadly neutralizing antibodies against human immunodeficiency virus (HIV) when delivered systemically [15]. This has led to a recent clinical trial in which this approach has shown a good safety profile [16].

2. Therapeutic Antibodies

2.1. Conventional and Heavy-Chain Antibodies

The field of personalized therapy using monoclonal antibodies (mAbs) has been in continuous expansion for more than three decades, when the first therapeutic antibody was approved for clinical use [17]. The antibody market has become dominant in the biopharmaceutical industry since 2009 [18], with numerous mAbs marketed in the US and the EU for the treatment of a wide array of diseases including cancer, autoimmune diseases and infections [19,20]. Despite the great success achieved by mAbs, several limitations, such as poor tissue penetration, immunogenicity, and high production costs, suggest that there is still room for improvement.

Conventional antibodies are complex molecules composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds and non-covalent interactions, forming a Y-shaped heterotetramer (Figure 1A). They are large molecules, with a molecular size of 150 kDa. The C-terminal halves of the heavy chains comprise the crystallizable fragment (Fc), which grants the antibody with secondary functions such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). The light chain and the two N-terminal domains of the heavy chain comprise the antigen-binding fragment (Fab). Antigen recognition is provided by the variable domains of the heavy (VH) and light (VL) chains, specifically by three hypervariable loops in each domain that comprise the complementary-determining regions (CDRs 1, 2,
and 3), flanked by four more conserved regions known as framework regions (FRs 1, 2, 3, and 4) [21].

![Figure 1. Graphical representation of conventional and heavy-chain antibodies. (A) Schematic structure of a conventional IgG antibody, composed by two heavy and two light chains, and a camelid heavy-chain antibody, consisting of two heavy chains. (B) Nanobody-based engineered molecules. scFv, single-chain fragment variable.](image)

The large and complex structure of conventional antibodies leads to several drawbacks that have prevented the widespread use of these molecules. Due to their complexity and posttranslational modifications, therapeutic mAbs are generally expressed in mammalian cells, leading to high production costs [22]. mAbs have a limited physicochemical stability [23], but once administered, they have a long serum half-life that may cause toxicities related to the treatment [22]. Although the technology for generation of fully humanized antibodies has improved their immunogenic profile, protein aggregation is still a concern because it can increase their immunogenicity while decreasing activity [24,25]. In addition, the large size of mAbs can obstruct their homogeneous distribution in tissues, especially in solid tumors where penetration tends to be inefficient [26], and in the central nervous system, due to their inability to cross the blood–brain barrier [27].

Naturally occurring heavy-chain antibodies (HCAbs) were found in camelids (dromedaries, camels, llamas, alpacas, guanacos, and vicuñas) nearly 30 years ago [28]. These antibodies are homodimers consisting solely of two identical heavy chains, lacking both the light chain and the constant domain 1 (C\textsubscript{H1}) of the heavy chain (Figure 1A). As a result, they are smaller than conventional antibodies, having a molecular mass of approximately 95 kDa. The variable antigen-binding domain of HCAbs (called V\textsubscript{H}H) retains full antigen-binding potential despite lacking the light chain. With dimensions of 4 nm × 2.5 nm × 3 nm, the V\textsubscript{H}H domain is considered to be the smallest naturally occurring antigen-binding fragment to date and has inspired the company Ablynx to coin the term “nanobody” [29,30].
2.2. Nanobodies

Structurally, nanobodies are similar to the V\textsubscript{H} domain of conventional antibodies, with four FRs and three CDRs. The homology between nanobodies and the V\textsubscript{H} domain of human immunoglobulins of family III is above 80% [31]. Despite this high level of homology, there are some key differences between V\textsubscript{H} and V\textsubscript{H}H domains. First, there is an increased frequency of polar amino acids in the FR2 of nanobodies compared to human antibodies. As a result, nanobodies present higher hydrophilicity, leading to an increased solubility in polar solvents and enhanced physicochemical stability compared to the variable fragment of conventional antibodies [32]. Second, the CDR3 tends to be longer in nanobodies than in conventional antibodies, having on average of 18 amino acids versus 14 amino acids in human antibodies. In nanobodies, the CDR3 is the main region implicated in antigen binding, assisted by CDR2 and CDR3, and some FR residues. This extended CDR3 loop is able to form finger-like structures or convex paratopes, allowing the binding to small cavities or concave epitopes (mainly conformational epitopes), such as catalytic sites of enzymes. In contrast, conventional antibodies are better at recognizing small chemical groups (haptens), peptides, or flat epitopes on proteins. These differences in antigen preference suggest non-overlapping functions for both types of antibodies [33,34].

The unique features of nanobodies make them attractive biotechnological tools for many applications. Their single-domain nature and small size simplify their genetic manipulation, and different relatively simple strategies can be used to generate specific nanobodies [35]. V\textsubscript{H}H libraries can be generated from naïve [36,37] or immunized animals [38], with full retention of functional diversity as no repairing of V\textsubscript{L} and V\textsubscript{H} domains is required, in contrast to conventional antibody libraries. Synthetic libraries can also be used, replacing animal experimentation [39,40]. Selection of target-specific nanobodies from these libraries can be performed through different techniques, such as phage or yeast display [35], and subsequent in vitro affinity maturation might improve binding properties [41]. Furthermore, genetic manipulation after the selection of nanobodies is facilitated due to their single-domain nature, making it possible to design multivalent formats of nanobodies or fusing them to other proteins (Figure 1B) [42].

Nanobodies have been successfully expressed in different systems obtaining high yields, including bacteria, yeast, plant cells, insect cells, and mammalian cells, as revised elsewhere [43]. This is possible thanks to their high solubility and physicochemical stability, single-domain nature, and the fact that posttranslational modifications are not needed. The possibility of using inexpensive systems such as \textit{E. coli} for nanobody production makes them very attractive tools for many applications.

2.3. The Therapeutic Potential of Nanobodies

Although the development of nanobodies for research and diagnostic purposes has experienced exponential growth in the last decade, advances in nanobody-based therapies have been more modest. The small size of nanobodies can be a double-edged sword for therapy: on the one hand, they show a homogenous distribution and a high and fast tissue penetration when delivered in vivo, but on the other hand, their serum half-life is very short, as their size is below the renal filtration cutoff of ~60 kDa [44]. While this characteristic is interesting for certain diagnostic applications such as molecular imaging [45], where fast blood clearance is desirable, it represents an obstacle for long-term therapeutic purposes. Several strategies can be employed to improve the pharmacokinetics of nanobodies, including fusion to an albumin-binding nanobody [46], or to an Fc domain [47].

Currently, numerous nanobody-based therapeutics are under clinical trials for the treatment of a variety of diseases, including cancer, autoimmune diseases, and viral infections [34], which are summarized in Table 1. One of the main concerns of using antibodies in humans is their potential immunogenicity, especially upon repeated administrations. Immunogenicity of nanobodies is normally low due to the high level of homology between nanobodies and human V\textsubscript{H} domain [48]. In addition, humanization of nanobodies can be performed to reduce potential adverse effects [49]. A phase I clinical trial using
a non-humanized nanobody showed no adverse effects, although it was administered only once for imaging purposes [50]. In another study, development of hepatotoxicity led to the early termination of phase I clinical evaluation of TAS266, an agonist humanized tetravalent nanobody targeting Death Receptor 5. Preexisting antibodies against TAS266 were found in those patients that developed adverse effects [51]. Although autoantibodies against framework regions of human \( V_H \) domains can be found in a proportion of healthy individuals [52], TAS266 immunogenicity may be more related to its artificial tetrameric nature and strong biological activity [51], as no adverse events have been described for other bivalent or trivalent nanobodies [48]. Recently, a platform for the generation of fully human heavy-chain antibodies in genetically engineered rats has been described [53]. This kind of strategy could offer in the future a straightforward procedure for the generation of human nanobodies with an improved safety profile for clinical use.

### Table 1. Therapeutic nanobodies in clinical trials.

| Drug Name(s)     | Format                  | Nanobody's Target(s)                  | Indication                          | Current Status          | Clinical Trial | Sponsor/Ref.                     |
|------------------|-------------------------|---------------------------------------|-------------------------------------|-------------------------|----------------|----------------------------------|
| Caplacizumab     | Bivalent, monospecific  | Von Willebrand factor-A               | Acquired thrombotic thrombocytopenia purpura | FDA/EMA approved        | NCT02553317, NCT02878603 | Ablynx [54]                     |
| ALX-0081         |                         |                                       |                                     |                         |                |                                  |
| ALX-0681         |                         |                                       |                                     |                         |                |                                  |
| KN046            | Tetravalent, bispecific, Fc-fusion protein | CTLA-4, PD-L1                       | Advanced solid tumors and lymphoma | Phase II/III           | NCT03872791, NCT0474419, NCT04925947 | Alphamab, Weill Medical College [55] |
| Ozoralizumab     | Trivalent, bispecific   | TNFα (2), HSA                         | Rheumatoid arthritis                | Phase II               | NCT00995036, NCT01007175 | Ablynx [56]                     |
| ATN-103          |                         |                                       |                                     |                         |                |                                  |
| Vobarilizumab    | Bivalent, bispecific    | IL-6R, HSA                            | Rheumatoid arthritis, systemic lupus erythematosus | Phase II               | NCT02287922, NCT02437890 | Ablynx [56]                     |
| ALX-0061         |                         |                                       |                                     |                         |                |                                  |
| Sonelokimab      | Trivalent, bispecific   | IL-17F, IL-17A/F, HSA                 | Psoriasis                           | Phase II               | NCT02156466, NCT0384745 | Merck KGaA, Bond Avillion 2 Development LP [57] |
| M1095            |                         |                                       |                                     |                         |                |                                  |
| Lulizumab        | Monomeric, pegylated    | CD28                                  | Systemic lupus erythematosus, kidney transplantation | Phase II               | NCT02265744, NCT04903054 | Bristol-Myers Squibb [58]       |
| BMS931699        |                         |                                       |                                     |                         |                |                                  |
| ALX-0171         | Trivalent, monospecific | RSV F-protein                         | RSV lower respiratory tract infection | Phase II               | NCT02309320, NCT02979431 | Ablynx [59]                     |
| LMN-101          | Monomeric               | FlAA flagellin of *Campylobacter jejuni* | *C. jejuni* infection               | Phase II               | NCT04182490 | Lumen Bioscience                 |
| ARPI             | Monomeric               | Rotavirus                             | Rotavirus infection                 | Phase II               | NCT01259765 | Int. Centre for Diarrhoeal Disease Research-Bangladesh [60] |
| VHH batch 203027 |                         |                                       |                                     |                         |                |                                  |
| Envolimab        | Monospecific, Fc-fusion protein | PD-L1                               | Advanced solid tumors, multiple primary neoplasm | Phase II               | NCT03667170, NCT04182789, NCT04891198 | Alphamab, 3D Medicines [61]     |
| KN035            |                         |                                       |                                     |                         |                |                                  |
| INBRX-109        | Tetravalent, monospecific | Death receptor 5                      | Advanced solid tumors, conventional chondrosarcoma | Phase I/II             | NCT03715933, NCT04950705 | Inhibrx                          |
| KN044            | Monospecific, Fc-fusion protein | CTLA-4                              | Advanced solid tumors               | Phase I                | NCT04126590 | Intellercrown Pharm.             |
| ALX-0141         | Trivalent, bispecific   | RANKL (2), HSA                        | Osteoporosis and bone metastasis    | Phase I                |                | Ablynx                           |
| M6495            | Bivalent, bispecific    | ADAMTS-5, HSA                        | Osteoarthritis                      | Phase I                | NCT03583346 | Merck KGaA [62]                  |
Table 1. Cont.

| Drug Name(s) | Format | Nanobody's Target(s) | Indication | Current Status | Clinical Trial | Sponsor/Ref. |
|--------------|--------|----------------------|------------|---------------|----------------|--------------|
| ES101 INBRX-105 | Tetravalent, bispecific, Fc-fusion protein | PD-L1, CD137 | Advanced solid tumors | Phase I | NCT03809624 NCT04009460 | Elpiscience, Inhibrx |
| ES102 INBRX-106 | Hexavalent, monospecific, Fc-fusion protein | OX40 | Advanced solid tumors | Phase I | NCT04198766 NCT04730843 | Elpiscience, Inhibrx |
| BCMA nanobody CAR-T cells | Nanobody-based chimeric antigen receptor | BCMA | Relapsed/Refractory Myeloma | Phase I | NCT03664661 | Henan Cancer Hospital |
| CD19/CD20 bispecific CAR-T cells | Nanobody-based bispecific chimeric antigen receptor | CD19/CD20 | B-Cell Lymphoma | Phase I | NCT03881761 | Henan Cancer Hospital |
| aPD1-MSLN-CAR T cells | MSLN-CAR T cells secreting anti-PD-1 nanobody | PD-1 | Advanced solid tumors | Phase I | NCT04503980 NCT04489862 | Shanghai Cell Therapy Group, Wuhan Union Hospital |
| ALX-0651 | Biparatopic, monospecific | CXCR4 | Multiple myeloma, non-Hodgkin’s lymphoma | Phase I terminated | NCT01374503 | Ablynx |
| TAS266 | Tetrameric | Death receptor 5 | Advanced solid tumors | Phase I terminated | NCT01529307 | Novartis Pharm. [51] |

Abbreviations: CTLA-4, Cytotoxic T-Lymphocyte Antigen 4; PD-1, Programmed cell death 1; PD-L1, PD-1 ligand 1; TNF, tumor necrosis factor; HSA, human serum albumin; IL, interleukin; CD, cluster of differentiation; RSV, Respiratory Syncytial Virus; RANKL, ligand of receptor activator for nuclear factor-κB; ADAMTS-5, a disintegrin and metalloproteinase with thrombospondin motifs-5; BCMA, B cell maturation antigen; MSLN, mesothelin; CXCR4, C-X-C motif chemokine receptor 4.

Recently, the first nanobody-based therapeutic (caplacizumab) was approved by the Food and Drug Administration and the European Medicines Agency for treatment of acquired thrombotic thrombocytopenic purpura (aTTP) [63]. aTTP is a blood disorder in which the activity of von Willebrand factor (vWF)-cleaving protease ADAMTS-13 is highly inhibited, which leads to the formation of vWF-platelet aggregates and microvascular thrombosis. Caplacizumab is a bivalent nanobody with a molecular mass of 28 kDa that binds to vWF and inhibits platelet aggregation. Subcutaneous administration of caplacizumab has shown to reduce disease recurrence and aTTP-related deaths, compared to patients receiving placebo [54]. This groundbreaking approval could give a boost to the development of new nanobody-based therapies in the years to come.

2.4. Nanobodies and Gene Therapy

Delivery of therapeutic antibodies using gene therapy vectors has been in continuous progress for more than two decades [64], when the first attempt was reported using an adenoviral vector [65]. Viral vectors are the most used delivery vehicle in pre-clinical and clinical trials due to their remarkable gene delivery efficiency [66]. Several strategies to enhance the efficacy and safety of this type of therapies have been described, including regulation of expression using inducible promoters [67], and promoting tissue-specific gene transfer and expression, which can be obtained by selecting the appropriate vector, the route of administration, and tissue-specific promoters. Local expression would not only increase the bioavailability of the therapeutic antibody in the target organ, but also reduce its dissemination to the blood, preventing potential toxicities. Although AAV vectors have been widely used to express mAbs in vivo, expression of nanobodies with these vectors has only been recently explored.

Nanobodies are particularly suitable agents for gene therapy due to their small size and single-gene nature, which facilitates the design of multivalent constructs and nanobody-protein fusions (Figure 1B). Interestingly, nanobodies can be expressed both as extracellular and intracellular proteins, broadening their potential applications. Intracellular antibodies,
known as intrabodies, can be used to treat diseases caused by intracellular processes. Nanobodies have the advantage over mAb, single-chain fragment variable (scFv) and Fabs, of being highly stable even in the reducing environment of the cytoplasm, where they can fold properly in the absence of disulfide bonds [68,69]. Nevertheless, as this is not a general statement for all nanobodies, optimizing library design, selection methods, and sequence optimization is essential for attaining functional intrabodies [70,71].

This review focuses on the current preclinical achievements in nanobody gene therapy using AAV vectors for the treatment of various diseases including cancer, genetic, infectious, and cardiovascular diseases (Table 2 and Figure 2).

Table 2. AAVs to deliver nanobodies.

| AAV a | Nb Activity b | Nb Conformation c | Results d | Ref. |
|-------|---------------|-------------------|-----------|------|
| 9     | Blocks gelsolin cleavage | Heterodimer | Improved muscle contraction in A Gel mice | [72] |
| 9     | Blocks RyR2 phosphorylation | Monomer | Lower cardiac fibrosis after rat ischemic heart failure | [73] |
| 5     | Enhances α-syn degradation | Monomer-PEST | Motor function protection in PD rat model | [74] |
| 8     | Antithrombin blockade | Heterodimer | Restores hemostatic balance in hemophilia A/B mice | [75] |
| 8     | Neutralizes influenza virus HA | Homodimer | Protection against lethal influenza virus in mice | [76] |
| 9     | Multiple domains | | | [77] |
| 8     | Blocking of PD-1 | Monomer | Protection against MC38 tumor challenge | [78] |
| 1     | P2X7 modulation | Dimer | Protection against EG7 tumor challenge | [79] |
| –     | Blocks PTCH1 activity | Monomer | Hedgehog pathway activation | [80] |
| 2/1   | Actin targeting | Monomer-mNep | In vivo visualization of actin filaments | [81] |
| 1     | GFP targeting | Monomer | Delivery of recombinases to GFP-expressing cells | [82] |
| 2/1   | Dimer-Flp | | Provides Flp activity in GFP + cells | [83] |
| 2/1   | Monomer-Cre | | Provides Cre activity in GFP + cells | [84] |
| 5     | Monomer-Rpl10a | | Capture translating mRNAs from GFP + neurons | [85] |
| 2/8/9 | Nb fused to AAV capsid | | Redirecting the specificity of AAV particles | [86] |

a AAV serotype; b The nanobody (Nb) target protein is underlined; RyR2, ryanodine receptor 2; α-syn, α-synuclein; HA, hemagglutinin; PD-1, programmed death protein-1; P2X7, ATP-gated ion channel P2X7; PTCH1, Hedgehog receptor Patched1; PEST, PEST domain; mNep, far-red fluorescent protein mNeptune2; Rpl10a, large ribosomal subunit protein; A Gel, gelsolin amyloidosis; PD, Parkinson disease; GFP +, GFP-expressing cells.
3. AAV Vectors Expressing Nanobodies for Treatment of Genetic Disorders

The use of gene therapy to treat genetic disorders is usually based on the delivery of the correct gene to target cells through an appropriate vector. However, some genetic diseases may also benefit from the use of therapeutic antibodies that target proteins or altered protein modifications that contribute to the pathogenesis of the disease. In this scenario, the use of antibody gene therapy is of particular interest, since it would be more cost-effective than repeated administration of antibody proteins. AAV vectors expressing therapeutic nanobodies have been used in experimental models of genetic diseases that include gelsolin amyloidosis (AGel) and hemophilia A and B.

AGel is an autosomal dominantly inherited disease that is produced by a point mutation in the gelsolin gene. This mutation results in sequential cleavage of gelsolin by furin and membrane type 1-matrix metalloproteinase (MT1-MMP) during its secretion, leading to the production of a small 8-kDa peptide that aggregates, forming cross-beta-sheet amyloid fibrils and plaques. AGel patients usually experience neurological, ophthalmological, and dermatological symptoms, with no specific treatments available. The group of Jan Gettemans (Ghent University, Belgium) had previously developed a llama nanobody against gelsolin (GSN Nb11) able to function as a molecular chaperone, blocking the cleavage of this protein by furin [87]. They showed the functionality of this approach by crossbreeding AGel mice with transgenic mice able to express GSN Nb11, which resulted in improved muscle contractility. They have recently evaluated the possibility of delivering GSN Nb11 from AAV vectors, something that could facilitate the use of this approach in the clinic [72]. For this purpose, they combined GSN Nb11 with a second nanobody able to inhibit MT1-MMP using a single bispecific format, with the aim to inhibit both proteolytic cleavages simultaneously. Interestingly, the two nanobodies were separated by an MT1-MMP-sensitive peptide sequence which alsofunctioned as an MT1-MMP pro-
An AAV9 vector administered to neonate AGel mice was able to successfully express this bispecific nanobody, which could be detected in serum at constant levels up to three months of age. Most importantly, AGel mice treated with the AAV9 expressing the bispecific nanobody showed a reduction in gelsolin amyloid burden, which translated into improved muscle contractile properties. In fact, in this study, the decline in the speed of muscle contraction during fatigue in treated AGel mice was very similar to the one observed for wild-type mice.

Hemophilia is a genetic disease in which a coagulation factor deficiency leads to spontaneous bleeding, as well as bleeding after injuries or surgery. Gene therapy for hemophilia A and B using AAV vectors expressing factors VIII and IX, respectively, has shown very promising results in clinical trials [88]. A different approach to avoid bleeding in these patients is the use of antithrombin inhibitors, since this protein blocks thrombin, the enzyme responsible to convert fibrinogen into fibrin. Antithrombin blockade can be achieved by llama-derived nanobodies, as shown recently by Barbon et al. [75]. As observed with other nanobodies mentioned in this review, their potency was very limited when used as monomers. However, by combining two different nanobodies with a flexible linker, it was possible to obtain a potent inhibitor of antithrombin activity even in the presence of heparin. This bispecific nanobody was able to restore hemostatic balance in hemophilia A mice when given as a recombinant protein. Most interestingly, similar results were obtained when the anti-antithrombin bispecific nanobody was produced from the liver in hemophilia A and B mice that received an AAV8 vector able to express it. The fact that AAV therapy in these mice was long-lasting and showed no toxicity suggests that this type of novel approach could be useful for treating different types of genetic clotting disorders.

4. AAV Vectors Expressing Nanobodies to Treat Heart Failure

An interesting approach to treat heart failure is based on the use of agents able to restore normal calcium circulation in cardiomyocytes, which is commonly altered in patients suffering a heart attack. This is usually due to an impaired function of ion channel proteins such as RyR2, sarco/endoplasmic reticulum Ca\(^2+\) ATPase, and the Na\(^+\)-Ca\(^2+\) exchanger. In the case of RyR2, hyperphosphorylation has been postulated as an important pathologic mechanism for myocardial injury and heart failure development, representing an interesting pharmacological target. Following this rationale, Li et al. developed a camel nanobody that could inhibit RyR2 phosphorylation [73]. In order to deliver this nanobody in vivo, they used an AAV9 vector and tested its functionality in a rat model of ischemic heart failure induced by coronary artery ligation. Nine weeks after injury, they observed that animals treated with AAV particles expressing the anti-RyR2 nanobody showed a significant improvement compared to untreated controls, indicated by a lower amount of cardiac fibrosis and a higher heart weight/body weight. These effects seemed to be mediated by a reduction in calcium leakage from cardiomyocytes in rats, improving their contractility. In this particular approach, the advantage of AAV delivery is based on the fact that the anti-RyR2 nanobody can only work intracellularly since the target protein is not secreted. This type of “intrabodies” can greatly benefit from the use of AAV vectors that can mediate their expression in target cells.

5. AAV Vectors Expressing Nanobodies for Treatment of Neurodegenerative Diseases

Neurodegenerative diseases are a group of heterogeneous illnesses including Alzheimer’s disease, Parkinson’s disease (PD), frontotemporal dementia, and Huntington’s disease, among others. Despite their clinical and epidemiological heterogeneity, most of them are characterized by precipitation of misfolded endogenous proteins, which leads to progressive neuronal dysfunction and death [89,90]. Different observations suggest that protein aggregates can spread from cell to cell, contributing to the pathology of these diseases [91]. Thus, many therapeutic strategies are aimed at preventing this phenomenon by using passive or active immunization. Protein aggregation inside cells can also be inhibited by
targeting the particular mRNA or protein responsible of the disease, alleviating neuronal toxicity [92,93]. AAVs are very attractive vectors for the delivery of therapeutic genes to the central nervous system due to their good safety profile, the neuronal tropism of some serotypes, and their long-term gene expression.

PD is the most common type of synucleinopathy, a group of diseases characterized by misfolding and aggregation of α-synuclein (α-syn). Therapeutic strategies for PD under investigation include the use of intrabodies against α-syn [94]. In particular, one nanobody (NbSyn87) and one scFv isolated from a non-immune human antibody library (VH14) [95] have shown protective activity in vitro [96]. Fusion of these intrabodies to a highly charged proteasomal-targeting signal (PEST) increased their solubility and enhanced the degradation of α-syn [97]. The therapeutic effect of the intrabodies has been evaluated in a PD rat model, in which overexpression of human α-syn in the substantia nigra (SN) was achieved using an AAV5 vector. Three weeks post-lesion, animals received a single injection of a second AAV5 vector expressing VH14 or NbSyn87 fused to PEST into the SN. Both intrabodies showed alleviation of pathogenic α-syn aggregation and improved motor functions; however, VH14 was superior at preserving overall nigrostriatal health. This could be attributed to the fact that NbSyn87 seemed to induce some degree of neuroinflammation [74]. These studies showed that intrabodies can be delivered to the central nervous system using AAV vectors and that they can have a beneficial effect on reducing intracellular protein accumulation. The development of combinatorial strategies that target protein accumulation both in intracellular and extracellular compartments hold great promise for the future.

6. AAV Vectors Expressing Nanobodies to Fight Viral Infections

Vaccines remain the main method of infectious disease control. However, their poor immunogenicity in certain high-risk patient groups, as well as the time needed to generate a potent immune response, are some of their shortcomings. In these cases, passive immunization using antibodies may be a feasible strategy to confer a quick protection during epidemics or pandemics [98]. Due to their unique properties, nanobodies have great potential as prophylactic and therapeutic agents to treat infectious diseases caused by a variety of pathogens such as viruses [99]. Several virus-neutralizing nanobodies have been described, including nanobodies against HIV [100], Hepatitis B virus [101], Middle East respiratory syndrome coronaviruses (MERS-CoV) [102], human respiratory syncytial virus (RSV) [103,104], rotavirus [105,106], influenza virus [103,107], and, more recently, SARS-CoV-2 [108–110].

Influenza virus represents a major public health concern, causing yearly epidemics and occasional pandemics. Due to the antigenic drift of the virus, vaccines have to be reformulated every year based on the predicted circulating virus strains for the upcoming season. Current vaccines usually induce strain-specific immunity, and they can be ineffective if there is a mismatch between the circulating viruses and vaccine strains [111]. In addition, these vaccines usually do not confer protection against emergent pandemic strains, such as the H1N1 in 2009, for which production of a strain-specific vaccine became necessary [112]. Limitations of seasonal influenza vaccines and the constant threat of a new influenza pandemic urge for the development of a wider range of strategies to tackle these viruses.

Broadly neutralizing antibodies (bnAbs) that recognize conserved influenza virus epitopes, especially within the hemagglutinin (HA) stem domain, have been isolated from humans, suggesting that a universal immunity against influenza virus may be possible [113]. Several conventional bnAbs against this protein are currently under clinical evaluation [114,115]. In terms of prophylaxis, this strategy would probably be too expensive and impractical to be widely implemented, because it would require 1) the formulation of a cocktail of bnAbs to achieve full coverage against both influenza A and B viruses, and 2) multiple administrations of high doses of bnAbs throughout the influenza season. A potential simpler strategy would be to deliver bnAbs using gene therapy. In this regard,
AAV vectors encoding conventional bnAbs have been tested in preclinical studies with promising results [116–118]. However, the bnAbs described to date lack of sufficient influenza A and B cross-reactivity, which means that a combination of at least two different bnAbs should be used to achieve full protection [119]. This could represent a problem when using AAV vectors due to its limited packaging capacity (<5 kb).

Interestingly, elucidation of the structure of two bnAbs in complex to HA has shown that, in both cases, the light chain is unnecessary for antigen binding [120,121]. Following this observation, different groups have attempted to isolate broadly neutralizing nanobodies against influenza. Hufton and colleagues [122] identified a nanobody (R1a-B6) with broad cross-subtype neutralizing activity in vitro. A bivalent format of this nanobody increased the breadth of cross-neutralization to more divergent subtypes, suggesting that the weak affinity interactions of monovalent R1a-B6 could be improved by dimerization [122]. The prophylactic potential of R1a-B6 was evaluated in a mouse model using AAV8 to express this nanobody as a monovalent molecule or fused to mouse IgG1 or IgG2a Fc domains [76]. A single dose of AAV8 given intramuscularly provided robust expression of R1a-B6-Fc fusions in sera, that was sustained for at least 6 months [76]. Mice in this study were challenged with lethal doses of two different pandemic strains H1N1 (A/California/07/2009) and H5N1 (A/Vietnam/1194/2004) at day 42 post-AAV administration. While mice in control groups succumbed to the infection quickly, mice expressing R1a-B6 fused to IgG1-Fc or IgG2a-Fc showed no symptoms of infection [76]. Mice treated with monovalent R1a-B6 showed a delay in the onset of symptoms but eventually succumbed to the infection, underlying the importance of Fc fusions [76]. It would be interesting to evaluate if Fc-mediated dimerization of nanobodies is capable of enhancing the breadth of cross-neutralization activity in vivo for other subtypes, as it was shown in vitro [122].

In another study, Larsen and colleagues isolated four broadly neutralizing nanobodies that were capable of neutralizing viruses from different groups of influenza A and B [77]. To increase their potency and breadth, the four nanobodies were fused using peptide linkers to generate a multiple-domain antibody (MDAb), which was additionally fused to Fc domains that conferred effector functions (human IgG1 or mouse IgG2a). This construct, named MD3606, showed great potential in prophylactic experiments when administered intravenously, outperforming bnAb CR9114 [113], which has been widely used in influenza virus research. MD3606 was also delivered using an intranasally administered AAV9, and, seven days later, mice were challenged with three different influenza viruses: H1N1 (A/Puerto Rico/8/34-MA), H3N2 (A/Hong Kong/1/68-MA), and B virus (B/Lee/40-MA). In this study, rAAV9-delivered MD306 provided complete protection in all cases, and abrogation of the Fc secondary functions substantially decreased the protective potential of MD3606 [77].

An interesting route to deliver AAV vectors expressing nanobodies against respiratory pathogens is the nasopharyngeal administration. By using this route, AAV9 vectors have been able to express antibodies up to four months in rhesus macaques [117]. Although the expression is not sustained, the rapid onset of protection observed in mice (seven days after AAV administration) and the breadth of neutralization make this an appealing strategy in pandemic scenarios, where vaccines are not immediately available. In addition, AAV9 can be re-administered in the airways without loss of efficiency [123,124], which could extend the time of protection. Moreover, combining intranasal and intramuscular AAV administration could provide the double benefit of local and prompt protection from nasal expression, and long-term systemic protection from transduced muscle cells [76,77]. Importantly, these routes of administration have been shown to circumvent pre-existing neutralizing antibodies to AAV capsids in mice [123] and rhesus macaques [125].

7. AAV Vectors Expressing Nanobodies for Cancer Treatment

The discovery of immune system checkpoints has been a major breakthrough for cancer therapy. Although immune checkpoints constitute a natural mechanism to avoid
toxicity and autoimmunity, many tumors express these molecules to escape immune attack [126]. One of the immune checkpoints that many tumors exploit to evade the immune response is the programmed death-1 (PD-1) / programmed death ligand 1 (PD-L1) axis, whose blocking by monoclonal antibodies (mAbs) has shown clinical efficacy in the treatment of many types of cancer [127]. However, this therapeutic strategy requires the repetitive systemic administration of high doses of mAbs that often leads to adverse effects, such as autoimmune events [128]. In addition, due to their large size (~150 kDa), mAbs show limited tumor penetration, which decreases their performance. To overcome these limitations, nanobodies represent very attractive tools because their small size allows high extravasation and tissue penetration [30]. However, as mentioned earlier, this can also be a downside, as they are rapidly eliminated from the bloodstream through renal clearance. One strategy to counteract this drawback could be the use of gene therapy vectors, such as AAV, that can continuously express nanobodies in vivo at therapeutic levels.

In fact, this approach was used by us to deliver in vivo a novel anti-PD-1 nanobody (Nb11) capable of blocking the PD-1 / PD-L1 interaction for mouse and human molecules [78]. This study showed that sustained AAV-mediated expression of the Nb11 prevented colon adenocarcinoma tumor formation in 30% of mice, significantly increasing survival without evidence of toxicity or autoimmune events. These data suggest that continuous expression of immunomodulatory nanobodies from long-term expression vectors could have antitumor effects with low toxicity.

In a different approach, Demeules et al. have expressed in vivo two nanobodies that can modulate the function of mouse P2X7, an ATP-gated ion channel with a crucial and complex role in cancer that is not completely understood [79]. Although there is evidence that P2X7 is associated with proinflammatory activity that could be pro-tumorigenic [129], it is also linked to the promotion of an adaptive antitumor immune response [130]. In order to elucidate the role of P2X7 in cancer, the authors generated AAV1 vectors encoding dimers of either antagonist or agonist nanobodies against P2X7 [79]. They were able to show that constant in situ expression of the P2X7 antagonistic bivalent nanobody induced a complete tumor regression in 40% of mice, significantly improving survival in a mouse lymphoma model. In contrast, AAV-mediated expression of the agonistic nanobody dimer did not significantly influence tumor growth in this model. By using nanobodies with different activities, this study demonstrated that P2X7 could be used as a target for anti-tumor treatment.

8. Other Applications of AAV Nanobody Delivery

Thanks to the beneficial properties of nanobodies as small entities with high stability and specificity, they are highly valued as versatile tools to study and manipulate proteins within living cells (Table 2). This unique property of nanobodies has led to the development of additional research applications that have also benefited from the use of AAV vectors for delivery, as it will be discussed in this section.

A simple example in which AAV delivery of nanobodies can be used to study biological functions is represented by a situation in which constant release of a nanobody is achieved in a particular type of cell, as in the case of the study presented above by Demeules et al. [79], which aimed to elucidate the function of P2X7 in the tumor context. Following a similar rationale, Zhang et al. described an agonist nanobody for the Hedgehog pathway, which is involved in embryonic tissue patterning and postembryonic regulation of tissue homeostasis and regeneration [80]. By specifically targeting conformational forms of Hedgehog receptor Patched1 (PTCH1), the nanobody stabilized this protein, disrupting its conformational cycle and, thus, its transport activity, leading to pathway activation. Although selective delivery of this nanobody by AAV vectors could increase tissue regeneration around transduced cells, avoiding systemic effects such us overgrowth of mesenchyme and fibrosis in multiple organs [131], this was not addressed in this study. Instead, the authors used systemic delivery to demonstrate that prolonged and sustained expression of anti-PTCH1 nanobody activated the Hedgehog signaling pathway in lingual
epithelium and skin. This approach can help to deepen the mechanistic aspects of this pathway and evaluate possible therapeutic applications.

A milestone in the use of nanobodies in research was the development of chromobodies, which consist of fusion proteins between an intracellular nanobody and a fluorescent protein. Chromobodies can be expressed from AAV vectors and are useful to visualize cellular structures and processes without interfering with the target’s function [132]. An example of this application is the chromobody formed by an anti-actin nanobody and the far-red fluorescent protein mNeptune2. The intracranial delivery of this chromobody with a neuron-specific AAV1/2 hybrid vector allowed to super resolve actin filaments and study dendritic spines dynamics in mice [81].

A more complex approach combining nanobodies and fluorescent proteins has been developed by Tang et al. to generate scaffolds for cell specific gene manipulation [133]. In this case, they generated green fluorescent protein (GFP)-specific nanobodies fused to complementing domains of transcription factors. Co-expression of these modified nanobodies and GFP in the cells allowed the formation of active transcription complexes that could also be easily visualized. This strategy has also been applied to control the activity of Cre recombinase by using two fragments of this protein, each one fused to a different GFP-specific nanobody [84]. In this system, called CRE-DOG, binding of each modified nanobody to GFP would allow the assembly of a functional Cre recombinase, leading to Cre/lox recombination (Figure 3A). As a proof of concept, they used an AAV vector to deliver CRE-DOG into the retina of transgenic mice expressing GFP in retinal ganglion cells, along with a second AAV expressing a Cre responsive element that would produce red fluorescence after recombination. As expected, recombination was specifically observed in GFP-expressing cells. The authors also proved that their results could be extrapolated to diverse brain regions, demonstrating that this could be a versatile strategy to manipulate genes in other GFP transgenic mice available for research.

![Figure 3](image_url)  
**Figure 3.** Schematic representation of research approaches using GFP/nanobodies scaffolds delivered by AAV vectors. (A) Cre recombinase dependent on GFP system, (B) Flp recombinase dependent on GFP system, (C) Immunoprecipitation of ribosome complexes dependent on GFP [82] and [85].
The same group has also created a conditional system in which the stability of a nanobody depends upon binding an antigen of interest [83]. For that purpose, they identified framework mutations that caused destabilization of nanobodies in the absence of the target antigen, leading to degradation by the ubiquitin proteasome system. Interestingly, any protein fused to the destabilized nanobody will also be degraded. This strategy was applied to control the stability of Flp recombinase by its fusion to a dimer of destabilized anti-GFP nanobodies. Therefore, Flp-mediated recombination was only possible in GFP-expressing cells (Figure 3B). By using this unique technology delivered by AAV vectors, they were able to express exogenous genes into GFP-expressing cells in the brain of transgenic mice.

Finally, Ekstrand et al. showed that transgenic mice expressing an anti-GFP nanobody fused to the large ribosomal subunit in a neuro-specific way, allows for gene expression profiling of GFP-expressing neurons, by capturing GFP complexes (including ribosomes and translating mRNAs) through immunoprecipitation (Figure 3C) [85]. The injection of a retrogradely transported adenovirus vector expressing GFP into a specific area of the brain allowed them to selectively profile pre-synaptic neurons projecting to that area. Going further, they were able to specifically determine the gene expression profile of dopaminergic neurons by using a Cre-conditional AAV5 vector to deliver the ribosome–nanobody construct into the brain of transgenic mice that express Cre recombinase under the control of the dopamine transporter promoter [85]. This work opens up the prospect of translational profiling of other neuronal subpopulations based on their connectivity.

9. Using Nanobodies to Re-Target AAV Vectors

An ideal in vivo gene therapy strategy involves not only an efficient expression of the therapeutic transgene, but also the specificity of such expression in the cells or tissue of choice. The tropism of AAVs is ubiquitous for most serotypes, and can be effectively exploited in some cases, such as when seeking high transgene expression in muscle by administering AAV1 or AAV8 vectors intramuscularly [7]. However, there are a wide variety of diseases in which the target cells are poorly transduced in vivo with the available serotypes, or in which administration of AAV intravenously is necessary, resulting in the transduction of unwanted tissues as a side effect. In these cases, the modification of the AAV capsid is proposed, in order to eliminate its natural tropism and provide it with a new and specific one. By means of genetic engineering, and with the help of the 3D structures of the different capsid serotypes, it is possible to insert peptides [134] or protein domains in the GH2/GH3 loop of VP1, the most prominent protrusion of the viral capsid [135].

To achieve a highly specific tropism, the recombinant fusion of antibodies to the aforementioned loop is a very attractive alternative. Unfortunately, this is a difficult task when using conventional antibodies, since their variable domain is made up of two different polypeptide chains and they are too large [136]. However, nanobodies have been proven to be good candidates to be fused with AAV2-VP1 [86].

Eichhoff et al. [86] retargeted the natural tropism of AAV2 capsid by inserting specific nanobodies for three structurally different membrane proteins: a GPI-anchored ectoenzyme (ARTC2.2), a single-span ectoenzyme type II (CD38), and a homotrimeric multi-span ion channel (P2X7). To this end, they genetically replaced seven amino acids of the VP1-GH2/GH3 loop (amino acids 453–459) by residues 110–130 of the corresponding nanobody. To prevent binding to the AAV2 natural receptor (heparan sulfate proteoglycan), arginines 585 and 588 were replaced by alanine. They showed that engineered AAVs were capable of transducing stably transfected HEK293 cells expressing the respective target proteins, achieving a 10–500-fold increase in transduction efficiency compared to the parental serotype. Similar results were obtained using other cells that express these proteins, such as mouse mammary carcinoma and lymphoma cell lines, as well as primary bone marrow cells that endogenously express CD38 or P2X7. The authors demonstrated that they could not only direct AAV tropism towards new cells, but also that retargeting was highly specific for cells expressing the corresponding protein. Interestingly, the nanobody-VP1 (AAV2) fu-
sion protein was effectively incorporated into the capsid of other serotypes (AAV8, AAV9, or AAV1P5), resulting in high yields of the corresponding mosaic AAV viral particles and leading to specific retargeting in vitro. Although these are promising results, in vivo studies have yet to be performed.

10. Conclusions and Future Perspectives

In modern medicine, a combination of new technologies usually allows the rapid advancement of efficient therapeutic treatments. One recent example is the combination of technologies to produce highly stable mRNA molecules and potent lipid formulations for in vivo delivery of nucleic acids, which has led to the development of efficient COVID-19 mRNA-based vaccines. In this review, we have shown that the numerous advantageous properties of nanobodies can be enhanced when they are delivered in vivo by AAV vectors able to: i) provide very long-term expression, and ii) deliver nanobodies both intra- or extra-cellularly. In this way, AAV nanobody delivery has shown great potential to cure a plethora of pathologies in preclinical models, ranging from genetic diseases to prevalent acquired malignancies, such as cancer, cardiovascular, infectious, and neurodegenerative diseases. In all these cases, the property of nanobodies to “block” a specific ligand, being it a foreign viral protein or an endogenous enzyme or protein with deleterious activity, is used to mediate a therapeutic effect that is maintained in time thanks to AAV delivery. In many of these cases, the use of nanobody dimers or multimers has shown more potency over the use of monomers, suggesting that future treatments based on this technology will probably require this strategy. In some cases, nanobodies have also been fused to proteins that increase their stability and half-life, something particularly interesting given their rapid renal elimination when delivered systemically. The good news is that, with nanobodies being so small, AAV vectors can easily accommodate genes coding for several nanobodies or for nanobodies fused to other proteins. The use of AAV-delivered nanobodies is not only limited to therapeutic purposes but has also found a niche in more basic research. This is due to the fact that nanobodies can also tamper with the activity of normal cellular proteins in a very specific way, which facilitates the discovery of new biological functions. A particular application of nanobodies for research is the use of protein domains fused to nanobodies specific for reporter proteins, such as GFP. In this case, the functional protein can only be reconstituted when their nanobody-fused domains bind to GFP, allowing to study more precisely its function or limiting its activity in reporter cells.

Although AAV delivery of nanobodies is still limited to a few preclinical models, the promising results obtained in these studies, together with the high safety profile shown by AAV vectors and nanobodies in clinical trials, suggest that this type of new therapy could soon be translated to the clinic.

Author Contributions: N.S.-P., C.S. and L.V. wrote and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the following grants: Instituto Salud Carlos III financed with Feder Funds P120/00415 (“A way to make Europe”), Gobierno de Navarra. Departamento de Salud 64/2019 (co-financed at 50% by the European Regional Development Fund through the FEDER Operational Program 2014–2020 of Navarra: “European Union. European Regional Development Fund. A way to make Europe”). NSP received a “Ayudas predoctorales de investigación biomédica AC” fellowship.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: N.S.-P., C.S. declare no conflict of interest. L.V. declares being a co-founder of Nanogrow Biotech, a startup that develops nanobodies for pharmaceutical applications.
References

1. Balakrishnan, B.; Jayandharan, G. Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy. Curr. Gene Ther. 2014, 14, 86–100. [CrossRef]

2. Wang, D.; Tai, P.W.L.; Gao, G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat. Rev. Drug Discov. 2019, 18, 358–378. [CrossRef]

3. Penaud-Budloo, M.; François, A.; Clément, N.; Ayuso, E. Pharmacology of Recombinant Adeno-associated Virus Production. Mol. Ther. Methods Clin. Dev. 2018, 8, 166–180. [CrossRef] [PubMed]

4. Li, C.; Samulski, R.J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 2020, 21, 255–272. [CrossRef]

5. Grimm, D.; Kay, M. From Virus Evolution to Vector Revolution: Use of Naturally Occurring Serotypes of Adeno-associated Virus (AAV) as Novel Vectors for Human Gene Therapy. Curr. Gene Ther. 2005, 3, 281–304. [CrossRef] [PubMed]

6. Colella, P.; Ronzitti, G.; Minguozzi, F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. Mol. Ther. Methods Clin. Dev. 2018, 8, 87–104. [CrossRef]

7. Keeler, A.M.; Flotte, T.R. Recombinant Adeno-Asssociated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? Annu. Rev. Virol. 2019, 6, 601–621. [CrossRef] [PubMed]

8. He, X.; Urip, B.A.; Zhang, N.; Nang, C.C.; Feng, B. Evolving AAV-delivered therapeutics towards ultimate cures. J. Mol. Med. 2021, 99, 593–617. [CrossRef]

9. Smith, R.H. Adeno-associated virus integration: Virus versus vector. Gene Ther. 2008, 15, 817–822. [CrossRef]

10. Hagedorn, C.; Schnödt-Fuchs, M.; Boehme, P.; Abdelrazik, H.; Lipps, H.J.; Büning, H. S/MAR Element Facilitates Episomal Long-Term Persistence of Adeno-Associated Virus Vector Genomes in Proliferating Cells. Hum. Gene Ther. 2017, 28, 1169–1179. [CrossRef]

11. Linden, R.M.; Winocour, E.; Berns, K.I. The recombination signals for adeno-associated virus site-specific integration. Proc. Natl. Acad. Sci. USA 1996, 93, 7966–7972. [CrossRef]

12. Recchia, A.; Mavilio, F. Site-Specific Integration by the Adeno-Associated Virus Rep Protein. Curr. Gene Ther. 2011, 11, 399–405. [CrossRef]

13. Shao, W.; Earley, L.F.; Chai, Z.; Chen, X.; Sun, J.; He, T.; Deng, M.; Hirsch, M.L.; Ting, J.; Samulski, R.J.; et al. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction. JCI Insight 2018, 3. [CrossRef] [PubMed]

14. Verdera, H.C.; Kuranda, K.; Minguozzi, F. AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer. Mol. Ther. 2020, 28, 723–746. [CrossRef]

15. Sherpa, C.; Le Grice, S.F.J. Adeno-Associated Viral Vector Mediated Expression of Broadly-Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target. Curr. HIV Res. 2020, 18, 114–131. [CrossRef]

16. Priddy, F.H.; Lewis, D.J.M.; Gelderblom, H.; Hassanin, H.; Streetfield, C.; LaBranche, C.; Hare, J.; Cox, J.H.; Dally, L.; Bendel, D.; et al. Adeno-associated virus vectorated immunoprophylaxis to prevent HIV in healthy adults: A phase 1 randomised controlled trial. Lancet HIV 2019, 6, e230–e239. [CrossRef]

17. Ecker, D.M.; Jones, S.D.; Levine, H.L. The therapeutic monoclonal antibody market. MAbs 2015, 8, 127–133. [CrossRef] [PubMed]

18. Cui, Y.; Cui, P.; Chen, B.; Li, S.; Guan, H. Monoclonal antibodies: Formulations of marketed products and recent advances in novel delivery system. Drug Dev. Ind. Pharm. 2017, 43, 519–530. [CrossRef] [PubMed]

19. Grilo, A.L.; Mantalaris, A. The Increasingly Human and Profitable Monoclonal Antibody Market. Trends Biotechnol. 2019, 37, 9–16. [CrossRef] [PubMed]

20. Ghagane, S.C.; Purunik, S.I.; Gan, S.H.; Hirerath, M.B.; Nerli, R.B.; Ravishankar, M.V. Frontiers of monoclonal antibodies: Applications in medical practices. Hum. Antibodies 2018, 26, 135–142. [CrossRef]

21. Buss, N.A.P.S.; Henderson, S.J.; McFarlane, M.; Shenton, J.M.; De Haan, L. Monoclonal antibody therapeutics: History and future. Curr. Opin. Pharmacol. 2012, 12, 615–622. [CrossRef]

22. Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br. J. Pharmacol. 2009, 157, 220–233. [CrossRef] [PubMed]

23. Le Basle, Y.; Chennell, P.; Tokhadze, N.; Astier, A.; Sautou, V. Physicochemical Stability of Monoclonal Antibodies: A Review. Br. J. Pharm. Sci. 2020, 109, 169–190. [CrossRef]

24. Filipe, V.; Hawe, A.; Schellekens, H.; Jiskoot, W. Aggregation and Immunogenicity of Therapeutic Proteins. In Aggregation of Therapeutic Proteins; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2010; pp. 403-433.

25. Ahmadi, M.; Bryson, C.J.; Cloake, E.A.; Welch, K.; Filipe, V.;romeijn, S.; Hawe, A.; Jiskoot, W.; Baker, M.P.; Fogg, M.H. Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm. Res. 2015, 32, 1383–1394. [CrossRef] [PubMed]

26. Cruz, E.; Kayser, V. Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy. Biol. Targets Ther. 2019, 13, 33–51. [CrossRef] [PubMed]

27. Yu, Y.J.; Watts, R.J. Developing Therapeutic Antibodies for Neurodegenerative Disease. Neurotherapeutics 2013, 10, 459–472. [CrossRef]

28. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hammers, C.; Songa, E.B.; Bendahman, N.; Hammers, R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363, 446–448. [CrossRef]

29. Sheridan, C. Ablynx’s nanobody fragments go places antibodies cannot. Nat. Biotechnol. 2017, 35, 1115–1118. [CrossRef]
30. Yang, E.Y.; Shah, K. Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics. Front. Oncol. 2020, 10, 1182. [CrossRef]
31. Nguyen, V.K.; Hamers, R.; Wyns, L.; Muyldermans, S. Camel heavy-chain antibodies: Diverse germline V(H)H and specific mechanisms enable the antigen-binding pocket. EMBO J. 2000, 19, 921–930. [CrossRef]
32. Barnas, P.; Hambach, J.; Koch-Nolte, F. Nanobodies and Nanobody-Based Human Heavy Chain Antibodies as Antitumor Therapeutics. Front. Immunol. 2017, 8, 1603. [CrossRef] [PubMed]
33. Muyldermans, S. Nanobodies: Natural Single-Domain Antibodies. Annu. Rev. Biochem. 2013, 82, 775–797. [CrossRef] [PubMed]
34. Jovčevska, I.; Muyldermans, S. The Therapeutic Potential of Nanobodies. BioDrugs 2020, 34, 11–26. [CrossRef]
35. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Generation of synthetic nanobodies and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 2018, 293, 3411–3422. [CrossRef] [PubMed]
36. Godakova, S.A.; Noskov, A.N.; Vinogradova, I.D.; Ugrimovua, G.A.; Soloyvey, A.I.; Esmagambetov, I.B.; Tukhvatulin, A.I.; Logunov, D.Y.; Naroditsky, B.S.; Scheblyakov, D.V.; et al. Camelid VHVs fused to human Fc fragments provide long-term protection against botulinum neurotoxin a in mice. Toxins 2019, 11, 464. [CrossRef] [PubMed]
37. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Immunogenicity Risk Profile of Nanobodies. Front. Immunol. 2021, 12, 578. [CrossRef] [PubMed]
38. Godakova, S.A.; Noskov, A.N.; Vinogradova, I.D.; Ugrimovua, G.A.; Soloyvey, A.I.; Esmagambetov, I.B.; Tukhvatulin, A.I.; Logunov, D.Y.; Naroditsky, B.S.; Scheblyakov, D.V.; et al. Camelid VHVs fused to human Fc fragments provide long-term protection against botulinum neurotoxin a in mice. Toxins 2019, 11, 464. [CrossRef] [PubMed]
39. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Immunoengineering Risk Profile of Nanobodies. Front. Immunol. 2021, 12, 578. [CrossRef] [PubMed]
40. Venkatesh, A.; Venkatesh, P.; Bhardwaj, P.; Joshi, S.; Cavanagh, J.; Luchansky, K.; Inoue, E.; Poignavent, V.; Vincke, C.; Ritzenthaler, C.; Muyldermans, S.; Monsion, B. Construction of High-Quality Camel Immune Antibody Libraries. In Phage Display; Humana Press: New York, NY, USA, 2018; pp. 169–187.
41. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Generation of synthetic nanobodies and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 2018, 293, 3411–3422. [CrossRef] [PubMed]
42. Godakova, S.A.; Noskov, A.N.; Vinogradova, I.D.; Ugrimovua, G.A.; Soloyvey, A.I.; Esmagambetov, I.B.; Tukhvatulin, A.I.; Logunov, D.Y.; Naroditsky, B.S.; Scheblyakov, D.V.; et al. Camelid VHVs fused to human Fc fragments provide long-term protection against botulinum neurotoxin a in mice. Toxins 2019, 11, 464. [CrossRef] [PubMed]
43. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Immunoengineering Risk Profile of Nanobodies. Front. Immunol. 2021, 12, 578. [CrossRef] [PubMed]
44. Venkatesh, A.; Venkatesh, P.; Bhardwaj, P.; Joshi, S.; Cavanagh, J.; Luchansky, K.; Inoue, E.; Poignavent, V.; Vincke, C.; Ritzenthaler, C.; Muyldermans, S.; Monsion, B. Construction of High-Quality Camel Immune Antibody Libraries. In Phage Display; Humana Press: New York, NY, USA, 2018; pp. 169–187.
45. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Generation of synthetic nanobodies and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 2018, 293, 3411–3422. [CrossRef] [PubMed]
46. Godakova, S.A.; Noskov, A.N.; Vinogradova, I.D.; Ugrimovua, G.A.; Soloyvey, A.I.; Esmagambetov, I.B.; Tukhvatulin, A.I.; Logunov, D.Y.; Naroditsky, B.S.; Scheblyakov, D.V.; et al. Camelid VHVs fused to human Fc fragments provide long-term protection against botulinum neurotoxin a in mice. Toxins 2019, 11, 464. [CrossRef] [PubMed]
47. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Immunoengineering Risk Profile of Nanobodies. Front. Immunol. 2021, 12, 578. [CrossRef] [PubMed]
48. Venkatesh, A.; Venkatesh, P.; Bhardwaj, P.; Joshi, S.; Cavanagh, J.; Luchansky, K.; Inoue, E.; Poignavent, V.; Vincke, C.; Ritzenthaler, C.; Muyldermans, S.; Monsion, B. Construction of High-Quality Camel Immune Antibody Libraries. In Phage Display; Humana Press: New York, NY, USA, 2018; pp. 169–187.
49. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Generation of synthetic nanobodies and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 2018, 293, 3411–3422. [CrossRef] [PubMed]
50. Godakova, S.A.; Noskov, A.N.; Vinogradova, I.D.; Ugrimovua, G.A.; Soloyvey, A.I.; Esmagambetov, I.B.; Tukhvatulin, A.I.; Logunov, D.Y.; Naroditsky, B.S.; Scheblyakov, D.V.; et al. Camelid VHVs fused to human Fc fragments provide long-term protection against botulinum neurotoxin a in mice. Toxins 2019, 11, 464. [CrossRef] [PubMed]
51. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Immunoengineering Risk Profile of Nanobodies. Front. Immunol. 2021, 12, 578. [CrossRef] [PubMed]
52. Godakova, S.A.; Noskov, A.N.; Vinogradova, I.D.; Ugrimovua, G.A.; Soloyvey, A.I.; Esmagambetov, I.B.; Tukhvatulin, A.I.; Logunov, D.Y.; Naroditsky, B.S.; Scheblyakov, D.V.; et al. Camelid VHVs fused to human Fc fragments provide long-term protection against botulinum neurotoxin a in mice. Toxins 2019, 11, 464. [CrossRef] [PubMed]
53. Ackaert, C.; Smiejkowska, N.; Xavier, C.; Sterckx, Y.G.J.; Denies, S.; Stijlemans, B.; Elkrim, Y.; Devoogdt, N.; Caveliers, V.; Lahoutte, T.; et al. Immunoengineering Risk Profile of Nanobodies. Front. Immunol. 2021, 12, 578. [CrossRef] [PubMed]
56. Van Roy, M.; Verwerken, C.; Beirnaert, E.; Hoefman, S.; Kolkman, J.; Vierboom, M.; Breedveld, E.; ’t Hart, B.; Poelmans, S.; Bontinck, L.; et al. The preclinical pharmacological activity of the high affinity anti-IL-6R Nanobody-ALX-0061 supports its clinical development in rheumatoid arthritis. *Arthritis Res. Ther.* 2015, 17, 135. [CrossRef] [PubMed]

57. Svecova, D.; Lubell, M.W.; Casset-Semanaz, F.; Mackenzie, H.; Gremmeling, R.; Krueger, J.G. A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. *J. Am. Acad. Dermatol.* 2019, 81, 196–203. [CrossRef]

58. Shi, R.; Honczerenko, M.; Zhang, S.; Fleener, C.; Mora, J.; Lee, S.K.; Wang, R.; Liu, X.; Shevell, D.E.; Yang, Z.; et al. Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects. *J. Clin. Pharmacol.* 2017, 57, 161–172. [CrossRef] [PubMed]

59. Déméules, M.; Scarpitta, A.; Abad, C.; Gondé, H.; Hardet, R.; Pinto-Espinoza, C.; Eichhoff, A.M.; Schäfer, W.; Haag, F.; Koch-Nolte, F.; et al. Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano). *Front. Oncol.* 2020, 10, 1699. [CrossRef]

60. Sarker, S.A.; Jäkel, M.; Sultana, S.; Alam, N.H.; Bardhan, P.K.; Chisti, M.J.; Salam, M.A.; Theis, W.; Hammarström, L.; Frenken, L.G.J. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. *J. Clin. Investig.* 2009, 121, 135–145. [CrossRef] [PubMed]

61. Zhang, F.; Wei, H.; Wang, X.; Bai, Y.; Wang, P.; Wu, J.; Jiang, X.; Wang, Y.; Cai, H.; Xu, T.; et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. *Cell Dis. 2017*, 3, 17004. [CrossRef]

62. Siebuhr, A.S.; Werkmann, D.; Bay-Jensen, A.-C.; Thudium, C.S.; Karsdal, M.A.; Serruys, B.; Ladel, C.; Michaelis, M.; Lindemann, S. The Anti-ADAMTS-5 Nanobody®M6495 Protects Cartilage Degradation Ext Vivo. *Int. J. Mol. Sci.* 2020, 21, 5992. [CrossRef]

63. Duggan, S. Caplacizumab: First Global Approval. *Drugs* 2018, 78, 1639–1642. [CrossRef]

64. Hollevoet, K.; Declerck, P.J. State of play and clinical prospects of antibody gene transfer. *EMBO Mol. Med.* 2017, 9, 1245–1253. [CrossRef] [PubMed]

65. Kunz, P.; Zinner, K.; Mücke, N.; Bartoschik, T.; Muylde, M.; Hoheisel, J.D. The structural basis of nanobodies unfolding reversibility and thermoresistance. *Sci. Rep.* 2018, 8, 7934. [CrossRef] [PubMed]

66. Vanrell, L.; Di Scala, M.; Blanco, L.; Otano, I.; Gil-Farina, I.; Baldim, V.; Paneda, A.; Beattie, S.G.; Chtarto, A.; et al. Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. *Mol. Ther.* 2011, 19, 1245–1253. [CrossRef] [PubMed]

67. Woods, J. Selection of Functional Intracellular Nanobodies. *SLAS Discov. Adv. Sci. Drug Discov. 2019*, 24, 703–713. [CrossRef]

68. Vanrell, L.; Di Scala, M.; Blanco, L.; Otano, I.; Gil-Farina, I.; Baldim, V.; Paneda, A.; Berraondo, P.; Beattie, S.G.; Chtarto, A.; et al. Devoogdt, N.; et al. AAV9 delivered bispecific nanobody attenuates amyloid burden in the gelsolin amyloidosis mouse model. *Hum. Mol. Genet.* 2017, 26, 1353–1364. [CrossRef]

69. Li, T.; Shen, Y.; Lin, F.; Fu, W.; Liu, S.; Wang, C.; Liang, J.; Fan, X.; Ye, X.; Tang, Y.; et al. Targeting RyR2 with a phosphorylation site-specific nanobody reverses dysfunction of failing cardiomyocytes in rats. *EASEB J.* 2019, 33, 7467–7478. [CrossRef] [PubMed]

70. Chatterjee, D.; Bhatt, M.; Butler, D.; De Geist, E.; Dobson, C.M.; Messer, A.; Kordower, J.H. Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson’s disease model. *npj Park. Dis.* 2018, 4, 25. [CrossRef] [PubMed]

71. Barbon, E.; Ayme, G.; Mohamadi, A.; Ottavi, J.; Kawecki, C.; Casari, C.; Verhenne, S.; Marmier, S.; van Wittenbergh, L.; Charles, S.; et al. Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors. *EMBO Mol. Med.* 2012, 4, e11298. [CrossRef]

72. Del Rosario, J.M.M.; Smith, M.; Zaki, K.; Risley, P.; Temperton, N.; Engelhardt, O.G.; Collins, M.; Takeuchi, Y.; Hufston, S.E. Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity. *Front. Immunol.* 2016, 7, 202. [CrossRef] [PubMed]

73. Laursen, N.S.; Frieden, R.H.; Zhu, X.; Jongeneelen, M.; Blokland, S.; Vermond, J.; Van Eijgen, A.; Tang, C.; Van Diepen, H.; Obmolova, G.; et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. *Science* 2018, 362, 598–602. [CrossRef] [PubMed]

74. Silva-Pilipich, N.; Martisova, E.; Cristina Ballesteros-Briones, M.; Hervas-Stubs, S.; Casares, N.; Gonzalez-Sapienza, G.; Smerdou, C.; Vanrell, L. Long-Term Systemic Expression of a Novel PD-1 Blocking Nanobody from an AAV Vector Provides Antitumor Activity without Toxicity. *Biomedicines* 2020, 8, 562. [CrossRef] [PubMed]
80. Zhang, Y.; Lu, W.-J.; Bulkley, D.P.; Liang, J.; Ralko, A.; Han, S.; Roberts, K.J.; Li, A.; Cho, W.; Cheng, Y.; et al. Hedgehog pathway activation through nanobody-mediated conformational blockade of the Patched sterol conduit. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 28838–28846. [CrossRef]

81. Wegner, W.; Ilgen, P.; Gregor, C.; van Dort, J.; Mott, A.C.; Steffens, H.; Willig, K.I. In vivo mouse and live cell STED microscopy of neuronal actin plasticity using far-red emitting fluorescent proteins. *Sci. Rep.* **2017**, *7*, 11781. [CrossRef]

82. Tang, J.C.Y.; Rudolph, S.; Cepko, C.L. Viral delivery of GFP-dependent recombinases to the mouse brain. In *Methods in Molecular Biology*; Human Press: New York, NY, USA, 2017; Volume 1642, pp. 109–126.

83. Tang, J.C.Y.; Drokhlyansky, E.; Etemad, B.; Rudolph, S.; Guo, B.; Wang, S.; Ellis, E.G.; Li, J.Z.; Cepko, C.L. Detection and manipulation of live antigen-expressing cells using conditionally stable nanobodies. *Elife* **2016**, *5*, e15312. [CrossRef]

84. Van Overbeke, W.; Ilgen, P.; Gregor, C.; van Dort, J.; Mott, A.C.; Steffens, H.; Willig, K.I. In vivo mouse and live cell STED microscopy of neuronal actin plasticity using far-red emitting fluorescent proteins. *Sci. Rep.* **2017**, *7*, 11781. [CrossRef]

85. Ekstrand, M.I.; Nectow, A.R.; Knight, Z.A.; Latcha, K.N.; Pomeranz, L.E.; Friedman, J.M. Molecular Profiling of Neurons Based on Connectivity. *Cell* **2014**, *157*, 1230–1242. [CrossRef] [PubMed]

86. Eichhoff, A.M.; Börner, K.; Albrecht, B.; Schäfer, W.; Baum, N.; Haag, F.; Körbelin, J.; Trepel, M.; Braren, I.; Grimm, D.; et al. Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors. *Mol. Ther. Methods Clin. Dev.* **2019**, *15*, 211–220. [CrossRef] [PubMed]

87. Van der Vaart, J.M.; Pant, N.; Wolvers, D.; Bezemer, S.; Hermans, P.W.; Bellamy, K.; Sarker, S.A.; van der Logt, C.P.E.; Svensson, L.; Verrrips, C.T.; et al. Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. *Vaccine* **2020**, *44*, 4130–4137. [CrossRef] [PubMed]
106. Garaicoechea, L.; Olichon, A.; Marcoppido, G.; Wigdorovitz, A.; Mozgovoj, M.; Saïf, L.; Surrey, T.; Parreño, V. llama-Derived Single-Chain Antibody Fragments Directed to Rotavirus VP6 Protein Possess Broad Neutralizing Activity In Vitro and Confer Protection against Diarrhea in Mice. J. Virol. 2008, 82, 9753–9764. [CrossRef] [PubMed]

107. Ibáñez, L.I.; De Filette, M.; Hultberg, A.; Verrips, T.; Temperton, N.; Weiss, R.A.; Vandevelde, W.; Schepens, B.; Vanlandschoot, P.; Saelens, X. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J. Infect. Dis. 2011, 203, 1063–1072. [CrossRef]

108. Schoof, M.; Faust, B.; Saunders, R.A.; Sangwan, S.; Rezelj, V.; Hoppe, N.; Boone, M.; Billesbolle, C.B.; Puchades, C.; Azumaya, C.M.; et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 2020, 370, 1473–1479. [CrossRef] [PubMed]

109. Hanke, L.; Vidakovics Perez, L.; Sheward, D.J.; Das, H.; Schulte, T.; Moliner-Morro, A.; Corcoran, M.; Achour, A.; Karlsson Hedestam, G.B.; Hallberg, B.M.; et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat. Commun. 2020, 11, 4420. [CrossRef]

110. Xiang, Y.; Nambulli, S.; Xiao, Z.; Liu, H.; Sang, Z.; Duprex, W.P.; Schneidman-Duhovny, D.; Zhang, C.; Shi, Y. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 2020, 370, 1479–1484. [CrossRef]

111. McMillan, C.L.D.; Young, P.R.; Watterson, D.; Chappell, K.J. The next generation of influenza vaccines: Towards a universal solution. Vaccines 2021, 9, 26. [CrossRef]

112. Rockman, S.; Laurie, K.; Barr, I. Pandemic influenza vaccines: What did we learn from the 2009 pandemic and are we better prepared now? Vaccines 2020, 8, 211. [CrossRef]

113. Dreyfus, C.; Lora, N.S.; Kwaks, T.; Zuiddgeest, D.; Khayat, R.; Ekiert, D.C.; Lee, J.H.; Metlagel, Z.; Bujny, M.V.; Jongeneelen, M.; et al. Highly conserved protective epitopes on influenza B viruses. Science 2012, 337, 1343–1348. [CrossRef]

114. Sparrow, E.; Friese, M.; Sheikh, M.; Torvaldsen, S.; Newall, A.; Passive immunization for influenza through antibody therapies, a review of the pipeline, challenges and potential applications. Vaccine 2016, 34, 5442–5448. [CrossRef]

115. Limberis, M.P.; Adam, V.S.; Wong, G.; Gren, J.; Kobasa, D.; Ross, T.M.; Kobinger, G.P.; Wilson, J.M. Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza. Sci. Transl. Med. 2013, 5, 187ra72. [CrossRef] [PubMed]

116. Limberis, M.P.; Wilson, J.M. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Proc. Natl. Acad. Sci. USA 2012, 109, 2014, 265–273. [CrossRef] [PubMed]

117. Sznol, M.; Ferrucci, P.F.; Hogg, D.; Atkins, M.B.; Wolter, P.; Guidoboni, M.; Lebbé, C.; Kirkwood, J.M.; Schachter, J.; Daniels, G.A.; et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J. Clin. Oncol. 2017, 35, 3815–3822. [CrossRef]

118. Bardhan, K.; Anagnostou, T.; Boussiotis, V.A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Hum. Gene Ther. 2012, 23, 733–741. [CrossRef] [PubMed]

119. Nieto, K.; Stahl-Hennig, C.; Leuchs, B.; Müller, M.; Gissmann, L.; Kleinschmidt, J.A. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. J. Virol. 2008, 82, 9753–9764. [CrossRef] [PubMed]

120. Limberis, M.P.; Wilson, J.M. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc. Natl. Acad. Sci. USA 2006, 103, 12993–12998. [CrossRef] [PubMed]

121. Nieto, K.; Stahl-Hennig, C.; Leuchs, B.; Müller, M.; Gissmann, L.; Kleinschmidt, J.A. Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Hum. Gene Ther. 2012, 23, 733–741. [CrossRef] [PubMed]

122. Greig, J.A.; Calcedo, R.; Grant, R.L.; Peng, H.; Medina-Jaszek, C.A.; Ahonkhai, O.; Qin, Q.; Roy, S.; Tretiakova, A.P.; Wilson, J.M. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. Vaccine 2016, 34, 6323–6329. [CrossRef] [PubMed]

123. Bardhan, K.; Anagnostou, T.; Boussiotis, V.A. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Hum. Gene Ther. 2012, 23, 733–741. [CrossRef] [PubMed]

124. Balazs, A.B.; Bloom, J.D.; Hong, C.M.; Rao, D.S.; Baltimore, D. Broad protection against influenza infection by vectored immunomodulation in mice. Nat. Biotechnol. 2013, 31, 647–652. [CrossRef] [PubMed]

125. Limberis, M.P.; Adam, V.S.; Wong, G.; Gren, J.; Kobasa, D.; Ross, T.M.; Kobinger, G.P.; Tretiakova, A.; Wilson, J.M. Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza. Sci. Transl. Med. 2013, 5, 187ra72. [CrossRef] [PubMed]

126. Limberis, M.P.; Wilson, J.M. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc. Natl. Acad. Sci. USA 2006, 103, 12993–12998. [CrossRef] [PubMed]

127. Saelens, X. Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection. J. Infect. Dis. 2011, 203, 2014, 265–273. [CrossRef] [PubMed]

128. Sznol, M.; Ferrucci, P.F.; Hogg, D.; Atkins, M.B.; Wolter, P.; Guidoboni, M.; Lebbé, C.; Kirkwood, J.M.; Schachter, J.; Daniels, G.A.; et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J. Clin. Oncol. 2017, 35, 3815–3822. [CrossRef]

129. De Marchi, E.; Orioli, E.; Pegoraro, A.; Sangaletti, S.; Portararo, P.; Curti, A.; Colombo, M.P.; Di Virgilio, F.; Adinolfi, E. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 2019, 38, 3636. [CrossRef]
130. Ghiringhelli, F.; Apetoh, L.; Tesniere, A.; Aymeric, L.; Ma, Y.; Ortiz, C.; Vermaelen, K.; Panaretakis, T.; Mignot, G.; Ullrich, E.; et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. *Nat. Med.* 2009, 15, 1170–1178. [CrossRef] [PubMed]

131. Horn, A.; Palumbo, K.; Cordazzo, C.; Dees, C.; Akhmetshina, A.; Tomcik, M.; Zerr, P.; Avouac, J.; Gusinde, J.; Zwerina, J.; et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. *Arthritis Rheum.* 2012, 64, 2724–2733. [CrossRef] [PubMed]

132. Wang, Y.; Fan, Z.; Shao, L.; Kong, X.; Hou, X.; Tian, D.; Sun, Y.; Xiao, Y.; Yu, L. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. *Int. J. Nanomed.* 2016, 11, 3287. [CrossRef] [PubMed]

133. Tang, J.C.Y.; Szikra, T.; Kozorovitskiy, Y.; Teixiera, M.; Sabatini, B.L.; Roska, B.; Cepko, C.L. A Nanobody-Based System Using Fluorescent Proteins as Scaffolds for Cell-Specific Gene Manipulation. *Cell* 2013, 154, 928–939. [CrossRef]

134. Müller, O.J.; Kaul, F.; Weitzman, M.D.; Pasqualini, R.; Arap, W.; Kleinschmidt, J.A.; Trepel, M. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. *Nat. Biotechnol.* 2003, 21, 1040–1046. [CrossRef] [PubMed]

135. Xie, Q.; Bu, W.; Bhatia, S.; Hare, J.; Somasundaram, T.; Azzi, A.; Chapman, M.S. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. *Proc. Natl. Acad. Sci. USA* 2002, 99, 10405–10410. [CrossRef] [PubMed]

136. Ried, M.U.; Girod, A.; Leike, K.; Bünig, H.; Hallek, M. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. *J. Virol.* 2002, 76, 4559–4566. [CrossRef] [PubMed]